

# Qinglin Pu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6153670/publications.pdf>

Version: 2024-02-01

7  
papers

131  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

189  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6001-6016.	6.4	8
2	Carbamate and <i>N</i> -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 389-396.	2.8	14
3	Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1380-1388.	2.8	11
4	Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1435-1440.	2.8	7
5	Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1678-1688.	2.8	9
6	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1548-1554.	2.8	44
7	Discovery of Amino-cyclobutane-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1530-1536.	2.8	38